Olympus Corporation of the Americas recalled 3 bronchovideoscopes on September 11, 2025, due to safety clarification updates. The recall affects 1,987 units distributed outside the US. Healthcare providers must stop using the device immediately to ensure patient safety.
Additional IFU updates to provide further clarification on safe and effective use of bronchoscopes when used in conjunction with laser, argon plasma coagulation, and high-frequency therapy equipment.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Olympus Corporation of the Americas or your healthcare provider for instructions
The recalled product is the Olympus Bronchovideoscope BF Type 1T150, with model number BF-1T150 and UDI 4953170308185. It is distributed nationwide in the US and internationally. The quantity recalled includes 3 units in the US and 1,987 units outside the US.
The recall addresses updates in the Instructions for Use (IFU) to clarify safe usage with laser, argon plasma coagulation, and high-frequency therapy equipment. The hazard level is classified as high due to the potential for improper use.
No specific incidents, injuries, or deaths have been reported related to this recall. The updates aim to prevent potential risks associated with improper use.
Patients and healthcare providers should stop using the Olympus Bronchovideoscope BF Type 1T150 immediately. Follow the recall instructions provided by Olympus Corporation of the Americas.
For further instructions, contact Olympus Corporation of the Americas or your healthcare provider. Additional information can be found on the FDA website.
Get notified about recalls in categories you care about.
Bristol-Myers Squibb recalled 12,778 vials of Opdualag injection on October 21, 2025. The recall stems from a lack of assurance of sterility. The affected products were distributed nationwide in the United States.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg, on October 10, 2025, due to failed impurities specifications. The recall affects several lot numbers distributed nationwide. Consumers must stop using the affected capsules immediately.
Lannett Company, Inc. recalled 46,848 bottles of Niacin Extended-release Tablets on October 10, 2025. The recall follows reports of failed dissolution specifications, which could affect medication effectiveness. Consumers should stop using the product immediately and consult healthcare providers for guidance.